Below is a graphic overview of VytlOne’s integrated approach to optimizing a health system’s pharmacy services, savings and revenue. In 340B support alone, we’ve generated over $500 million for the hospitals we serve — revenue those systems have used to positively impact the quality and scope of patient care they offer, in countless ways. Why … Read More
It’s no secret that the 340B Drug Pricing Program has been a lifeline for eligible health systems, enabling them to fill-in the massive revenue gaps inherent to the non-profit-hospital business model (and, in the process, support their mission of providing quality care to our nation’s most vulnerable patients) through access to discounted prescription refills. At … Read More
Based on our experience, it’s a claim we can make with 100% certainty. VytlOne has supported the 340B programs of more than 100 health systems and health centers since 2019. Altogether, we’ve generated nearly $1 billion in pharmacy-related savings for our clients. While the average 340B hospital’s revenues have decreased significantly since the 2020 advent … Read More
Why 340B vendors charging Percentage Of Revenue is wrong. From time to time, 340B hospitals are required to purchase non-eligible prescriptions at the Wholesale Acquisition Cost. When that happens, the costs of those medications often exceed reimbursement. Most 340B hospitals already operate on a loss-basis. Which is why, we believe, it’s so wrong for 340B … Read More
Since the advent of 340B ESP in 2020, drug manufacturers have imposed a raft of unlawful restrictions on 340B program savings. Nowhere have those restrictions been more punitive than with specialty pharmacy medications; drugs which typically represent the most expensive (and profitable) in manufacturers’ product lines. 340B restrictions from the drug manufacturers’ perspective That said, … Read More
Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when VytlOne launched its 340B Support Services division, we’ve managed the 340B programs of 18 health systems. We’ve generated more than $500 million in 340B Savings and Revenue. And yet, we’ve never served (or seen) a 340B health system with … Read More
The 340B-program landscape has changed dramatically. For the 340B program’s first 28 years after its 1992 inception, the basic list of Best Practices for eligible entities (the 340B basics, if you will) remained largely unchanged — aside from the dramatically-increased importance of using specialized software. But since the June, 2020 introduction of 340B ESP — … Read More
340B ESP and drug manufacturer restrictions are only part of the reason As we noted in a previous post, for 340B-eligible hospitals dealing with increasingly squeezed bottom lines, an in-house specialty pharmacy offers enormous savings and revenue potential. Some covered entities generate as much as 600% in specialty pharmacy revenue from 340B drugs as they … Read More
POST OUTLINE 1) Our process for recovering savings lost to 340B ESP Introduction / Overview Brief history of 340B-related manufacturer restrictions List of manufacturers currently imposing restrictions 2) How VytlOne overcomes 340B ESP restrictions on 340B pricing Establishing communications protocols Ensuring 340B ESP restores prices on schedule Recommendations for further reading Ensuring 340B ESP restores … Read More
